Viking Therapeutics (US:VKTX) — Company Overview, News & Financial Data

Viking Therapeutics logo
VKTXViking Therapeutics
Trade VKTX now
Viking Therapeutics primary media

About Viking Therapeutics

Viking Therapeutics (NASDAQ:VKTX) is a biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. Their portfolio consists of promising candidates aimed at treating conditions such as hypothyroidism, non-alcoholic fatty liver disease, and muscle wasting. Viking Therapeutics is dedicated to advancing these projects through clinical trials, with the ultimate objective of addressing unmet medical needs and improving patient lives. Through their rigorous research and innovative approach, they strive to develop effective treatments that can lead to better health outcomes for individuals affected by these disorders.

What is VKTX known for?

Snapshot

Public US
Ownership
2012
Year founded
26
Employees
San Diego, United States
Head office
Loading Map...

Operations

All Locations
San Diego, US

Products and/or services of Viking Therapeutics

  • VK2809 is in development for lipid disorders such as hypercholesterolemia and non-alcoholic steatohepatitis (NASH).
  • VK5211, aimed at treating patients recovering from hip fractures by enhancing lean body mass and bone density.
  • VK0214 targets X-linked adrenoleukodystrophy (X-ALD), a genetic disorder affecting the nervous system and adrenal glands.
  • VK2735 is being explored for its potential in treating autoimmune diseases, offering a new approach to immune modulation.
  • Development of a novel class of selective androgen receptor modulators (SARMs) for treating conditions associated with muscle and bone wasting.
  • Research into thyroid beta agonists, exploring innovative treatments for metabolic and cardiovascular diseases.

Viking Therapeutics executive team

  • Dr. Brian Lian Ph.D.President, CEO & Director
  • Mr. Gregory S. Zante CPAChief Financial Officer
  • Ms. Marianne ManciniChief Operating Officer
  • Mr. Michael MorneauVice President of Finance & Administration
  • Dr. Geoffrey E. Barker Ph.D.Chief Development Officer
  • Mr. Neil Aubuchon B.A., M.B.A.Chief Commercial Officer
  • Dr. Nils U. Olsson Ph.D.Senior Vice President of Technical Operations

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.